{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:53:23Z","timestamp":1780566803676,"version":"3.54.1"},"reference-count":59,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jtct.2022.03.011","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T10:36:11Z","timestamp":1647167771000},"page":"323.e1-323.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine\/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6426-6770","authenticated-orcid":false,"given":"Shuhei","family":"Kurosawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshimitsu","family":"Shimomura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidehiro","family":"Itonaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuho","family":"Najima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinobu","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kako","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiro","family":"Kawakita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Matsuoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1410-0830","authenticated-orcid":false,"given":"Yumiko","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuichi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6457-5052","authenticated-orcid":false,"given":"Hideyuki","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Imada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takafumi","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4404-2870","authenticated-orcid":false,"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Ishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.03.011_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.clml.2020.10.008","article-title":"Allogeneic stem-cell transplantation in patients with myelodysplastic syndromes and prevention of relapse","volume":"21","author":"Franke","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.jtct.2022.03.011_bib0002","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1182\/blood-2016-06-724500","article-title":"Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel","volume":"129","author":"de Witte","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0003","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1182\/asheducation-2016.1.478","article-title":"Transplantation for myelodysplastic syndromes: who, when, and which conditioning regimens","volume":"2016","author":"Saber","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.jtct.2022.03.011_bib0004","doi-asserted-by":"crossref","first-page":"3549","DOI":"10.1200\/JCO.2013.48.8114","volume":"31","author":"Nagler","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0005","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2013-07-514448","article-title":"Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI","volume":"122","author":"Copelan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0006","doi-asserted-by":"crossref","first-page":"3871","DOI":"10.1182\/blood-2013-08-519009","article-title":"Prospective cohort study comparing intravenous busulfan to total body irradiation in hematopoietic cell transplantation","volume":"122","author":"Bredeson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0007","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1056\/NEJMoa1004383","article-title":"Reduced mortality after allogeneic hematopoietic-cell transplantation","volume":"363","author":"Gooley","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.011_bib0008","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1182\/blood.V97.11.3390","article-title":"Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects","volume":"97","author":"McSweeney","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0009","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1182\/blood.V97.3.631","article-title":"Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation","volume":"97","author":"Giralt","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0010","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1007\/s00277-019-03653-7","article-title":"Increased opportunity for prolonged survival after allogeneic hematopoietic stem cell transplantation in patients aged 60-69 years with myelodysplastic syndrome","volume":"98","author":"Itonaga","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0011","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1053\/bbmt.2002.v8.pm12374451","article-title":"Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes","volume":"8","author":"Russell","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0012","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1182\/blood-2004-02-0414","article-title":"Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS","volume":"104","author":"de Lima","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0013","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/sj.bmt.1705770","article-title":"New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation: comparison with BuCy2","volume":"40","author":"Chae","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0014","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bbmt.2008.03.009","article-title":"Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML\/MDS","volume":"14","author":"Andersson","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0015","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5045\/kjh.2010.45.2.102","article-title":"Fludarabine-based myeloablative regimen as pretransplant conditioning therapy in adult acute leukemia\/myelodysplastic syndrome: comparison with oral or intravenous busulfan with cyclophosphamide","volume":"45","author":"Lee","year":"2010","journal-title":"Korean J Hematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0016","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1200\/JCO.2011.40.2362","article-title":"Randomized trial of myeloablative conditioning regimens: busulfan plus cyclophosphamide versus busulfan plus fludarabine","volume":"31","author":"Lee","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0017","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1016\/j.bbmt.2016.04.013","article-title":"Intravenous busulfan-based myeloablative conditioning regimens prior to hematopoietic cell transplantation for hematologic malignancies","volume":"22","author":"Pasquini","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0018","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.hemonc.2019.09.002","article-title":"Comparative effectiveness of busulfan\/cyclophosphamide versus busulfan\/fludarabine myeloablative conditioning for allogeneic hematopoietic cell transplantation in acute myeloid leukemia and myelodysplastic syndrome","volume":"13","author":"Patel","year":"2020","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"10.1016\/j.jtct.2022.03.011_bib0019","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1756-8722-6-15","volume":"6","author":"Liu","year":"2013","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0020","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/S1470-2045(15)00200-4","article-title":"Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial","volume":"16","author":"Rambaldi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0021","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/sj.leu.2404037","article-title":"Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablative versus reduced-intensity conditioning: the role of dose intensity","volume":"20","author":"Shimoni","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.03.011_bib0022","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1007\/s00277-015-2349-4","article-title":"Allogeneic transplantation with myeloablative FluBu4 conditioning improves survival compared to reduced intensity FluBu2 conditioning for acute myeloid leukemia in remission","volume":"94","author":"Magenau","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0023","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1016\/j.bbmt.2017.09.003","article-title":"Comparison of conditioning with fludarabine\/busulfan and fludarabine\/melphalan in allogeneic transplantation recipients 50 years or older","volume":"23","author":"Kawamura","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0024","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1182\/bloodadvances.2018021980","article-title":"Hematopoietic cell transplant for acute myeloid leukemia and myelodysplastic syndrome: conditioning regimen intensity","volume":"2","author":"Eapen","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtct.2022.03.011_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-021-01447-y","article-title":"Fludarabine\/busulfan versus busulfan\/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis","author":"Kurosawa","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0026","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.1200\/JCO.2008.20.9692","article-title":"Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia","volume":"27","author":"Ringden","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0027","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/bmt.2010.164","article-title":"Impact of intensity of conditioning therapy in patients aged 40-60 years with AML\/myelodysplastic syndrome undergoing allogeneic transplantation","volume":"46","author":"Khabori","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0028","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjh.13124","article-title":"Allogeneic haematopoietic cell transplantation with reduced-intensity conditioning for elderly patients with advanced myelodysplastic syndromes: a nationwide study","volume":"168","author":"Aoki","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0029","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0030","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1038\/s41409-021-01324-8","article-title":"Allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome in adolescent and young adult patients","volume":"56","author":"Shimomura","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0031","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","article-title":"Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data)","volume":"103","author":"Atsuta","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0032","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s12185-015-1907-9","article-title":"Scripts for TRUMP data analyses. Part II (HLA-related data): statistical analyses specific for hematopoietic stem cell transplantation","volume":"103","author":"Kanda","year":"2016","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0033","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/bmt.2015.297","article-title":"Impact of low-dose TBI on outcomes of reduced intensity conditioning allogeneic hematopoietic stem cell transplantation for AML","volume":"51","author":"Aoki","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0034","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/bmt.2010.280","article-title":"TBI during BM and SCT: review of the past, discussion of the present and consideration of future directions","volume":"46","author":"Hill-Kayser","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0035","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.2009.27.1460","article-title":"Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia","volume":"28","author":"Gyurkocza","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0036","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s12185-017-2341-y","article-title":"Prospective observational study on the first 51 cases of peripheral blood stem cell transplantation from unrelated donors in Japan","volume":"107","author":"Goto","year":"2018","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0037","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1002\/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B","article-title":"Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group","volume":"17","author":"D'Agostino","year":"1998","journal-title":"Stat Med"},{"key":"10.1016\/j.jtct.2022.03.011_bib0038","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1038\/sj.bmt.1703271","article-title":"Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling","volume":"28","author":"Klein","year":"2001","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0039","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1182\/blood-2014-10-609032","article-title":"Composite end point of graft-versus-host disease-free, relapse-free survival after allogeneic hematopoietic cell transplantation","volume":"125","author":"Holtan","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0040","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJM200106143442402","article-title":"Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors","volume":"344","author":"Laughlin","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.011_bib0041","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0042","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0043","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0044","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","author":"Cheson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.jtct.2022.03.011_bib0046","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software 'EZR' for medical statistics","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0047","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2016.70.7349","article-title":"Dose-reduced versus standard conditioning followed by allogeneic stem-cell transplantation for patients with myelodysplastic syndrome: A prospective randomized phase III study of the EBMT (RICMAC Trial)","volume":"35","author":"Kroger","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0048","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/cncr.27786","article-title":"Randomized study of 2 reduced-intensity conditioning strategies for human leukocyte antigen-matched, related allogeneic peripheral blood stem cell transplantation: prospective clinical and socioeconomic evaluation","volume":"119","author":"Blaise","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.jtct.2022.03.011_bib0049","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1200\/JCO.20.02308","article-title":"Augmented reduced-intensity regimen does not improve postallogeneic transplant outcomes in acute myeloid leukemia","volume":"39","author":"Craddock","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0050","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1007\/s00277-003-0654-9","article-title":"Allogeneic stem cell transplantation after a fludarabine\/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia","volume":"82","author":"Kroger","year":"2003","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0051","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/ejh.12214","article-title":"Positive impact of chronic graft-versus-host disease on the outcome of patients with de novo myelodysplastic syndrome after allogeneic hematopoietic cell transplantation: a single-center analysis of 115 patients","volume":"92","author":"Hiramoto","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtct.2022.03.011_bib0052","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/s41408-019-0192-x","article-title":"Graft-versus-MDS effect after unrelated cord blood transplantation: a retrospective analysis of 752 patients registered at the Japanese Data Center for Hematopoietic Cell Transplantation","volume":"9","author":"Ishiyama","year":"2019","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jtct.2022.03.011_bib0053","doi-asserted-by":"crossref","first-page":"6483","DOI":"10.1158\/1078-0432.CCR-20-1104","article-title":"Effects of acute and chronic graft-versus-myelodysplastic syndrome on long-term outcomes following allogeneic hematopoietic cell transplantation","volume":"26","author":"Konuma","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtct.2022.03.011_bib0054","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1056\/NEJMoa1611604","article-title":"Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation","volume":"376","author":"Lindsley","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jtct.2022.03.011_bib0055","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood-2016-12-754796","article-title":"Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation","volume":"129","author":"Yoshizato","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0056","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtct.2022.03.011_bib0057","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/bmt.2009.190","article-title":"Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: prognostic significance of pre-transplant IPSS score and comorbidity","volume":"45","author":"Lee","year":"2010","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0058","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.bbmt.2008.11.015","article-title":"IPSS poor-risk karyotype as a predictor of outcome for patients with myelodysplastic syndrome following myeloablative stem cell transplantation","volume":"15","author":"Nevill","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.03.011_bib0059","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1182\/blood-2013-12-542720","article-title":"Predictive factors for the outcome of allogeneic transplantation in patients with MDS stratified according to the revised IPSS-R","volume":"123","author":"Della Porta","year":"2014","journal-title":"Blood"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722001592?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722001592?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:05:00Z","timestamp":1763003100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722001592"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":59,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666636722001592"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.011","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myeloablative Versus Reduced-Intensity Conditioning With Fludarabine\/Busulfan for Myelodysplastic Syndrome: A Propensity Score-Matched Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}